Nancy Joseph‐Ridge

Author

Nancy Joseph‐Ridge

Also Known As

N JOSEPHRIDGE, N Joseph-Ridge, N. JOSEPH-RIDGE, N. Joseph-Ridge, N. Joseph‐Ridge, Nancy Joseph-Ridge, Nancy Joseph‐Ridge

Publications

4.2K

Citations

H-Index

Concepts

All Affiliations

University of Chicago University of Pennsylvania Pfizer (United States)University of Florida National Statistical Service of the Republic of Armenia

About

Nancy Joseph‐Ridge is an author at University of Chicago specializing in medicine, pharmacotherapy, and outcomes research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	1.1K
2	Endocrinology	2	2	152
3	Education	1	1	123
4	Health Sciences	1	1	48
5	Emergency Medicine	1	1	75

Nancy Joseph‐Ridge

Publications

4.1K

Citations

H-Index

Page 1

	Year	Citations
Febuxostat Compared with Allopurinol in Patients with Hyperuricemia and Gout Michael A. Becker, H. Ralph Schumacher, Robert L. Wortmann, New England Journal of Medicine	2005	1.3K
Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: A 28‐week, phase III, randomized, double‐blind, parallel‐group trial H. Ralph Schumacher, Michael A. Becker, Robert L. Wortmann, Arthritis Care & Research Renal InflammationPharmacotherapyGout FlaresRenal FunctionFebuxostat Versus Allopurinol	2008	623
Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. Katrine L. Wallace, Aylin Riedel, Nancy Joseph‐Ridge, PubMed	2004	427
Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: A twenty‐eight–day, multicenter, phase II, randomized, double‐blind, placebo‐controlled, dose‐response clinical trial examining safety and efficacy in patients with gout Michael A. Becker, H. Ralph Schumacher, Robert L. Wortmann, Arthritis & Rheumatism	2005	267
Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims. Aylin Riedel, Michael A. Nelson, Nancy Joseph‐Ridge, PubMed	2004	175
Pharmacokinetics and Pharmacodynamics of Febuxostat, a New Non-purine Selective Inhibitor of Xanthine Oxidase in Subjects with Renal Impairment Michael D. Mayer, Reza Khosravan, Laurent Vernillet, American Journal of Therapeutics	2005	153
The Impact of Gout on Work Absence and Productivity Nathan L. Kleinman, Richard A. Brook, Pankaj Patel, Value in Health ProductivityQuality Of LifeWorkforce DevelopmentHealthy Work EnvironmentEducation	2007	123
Pharmacokinetics, Pharmacodynamics and Safety of Febuxostat, a Non-Purine Selective Inhibitor of Xanthine Oxidase, in a Dose Escalation Study in Healthy Subjects Reza Khosravan, Brian Grabowski, Jingtao Wu, Clinical Pharmacokinetics Healthy SubjectsPharmacological StudyPharmacologyXanthine OxidasePharmacotherapy	2006	104
Febuxostat (TMX‐67), a Novel, Non‐Purine, Selective Inhibitor of Xanthine Oxidase, Is Safe and Decreases Serum Urate in Healthy Volunteers Michael A. Becker, James C. Kisicki, Reza Khosravan, Nucleosides Nucleotides & Nucleic Acids Molecular PharmacologyAdverse EventsUrologyRenal FunctionUrological Research	2004	96
Determinants of the Clinical Outcomes of Gout During the First Year of Urate-Lowering Therapy Michael A. Becker, Patricia MacDonald, Barbara Hunt, Nucleosides Nucleotides & Nucleic Acids First YearMedicineGouty ArthritisOutcomes ResearchGout Flare Incidence	2008	86

Page 1